US5788965A
(en)
*
|
1991-02-28 |
1998-08-04 |
Novo Nordisk A/S |
Modified factor VII
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
US5997864A
(en)
*
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
US5817788A
(en)
*
|
1991-02-28 |
1998-10-06 |
Zymogenetics, Inc. |
Modified factor VII
|
US5736364A
(en)
*
|
1995-12-04 |
1998-04-07 |
Genentech, Inc. |
Factor viia inhibitors
|
US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
CA2405709A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6905683B2
(en)
|
2000-05-03 |
2005-06-14 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
MXPA03001984A
(es)
|
2000-09-13 |
2003-08-29 |
Novo Nordisk Healthcare Ag |
Variantes de factor vii de coagulacion humano.
|
PL204888B1
(pl)
*
|
2000-09-13 |
2010-02-26 |
Novo Nordisk Healthcare Ag |
Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII
|
AU2002218029A1
(en)
|
2000-11-09 |
2002-05-21 |
The Scripps Research Institute |
Modified factor viia
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
ES2432967T3
(es)
|
2001-03-22 |
2013-12-05 |
Novo Nordisk Health Care Ag |
Derivados del Factor VII de coagulación
|
US7052868B2
(en)
|
2001-09-27 |
2006-05-30 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
JP2005507008A
(ja)
*
|
2001-11-02 |
2005-03-10 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
アポトーシスに関連した症状の治療のための、組織因子アゴニストまたは組織因子アンタゴニストの使用
|
US6858587B2
(en)
|
2001-11-02 |
2005-02-22 |
Novo Nordisk Pharmaceuticals, Inc. |
Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
|
RU2357751C2
(ru)
|
2001-12-21 |
2009-06-10 |
Ново Нордиск Хелт Кэр Аг |
Жидкая композиция полипептидов фактора vii
|
PT1499719E
(pt)
|
2002-04-30 |
2011-02-09 |
Bayer Healthcare Llc |
Variantes polipeptídicas do factor vii ou viia
|
EP2283856B1
(en)
|
2002-06-21 |
2017-09-20 |
Novo Nordisk Health Care AG |
Stabilised solid compositions of factor VIIa polypeptides
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
DK1549677T3
(da)
*
|
2002-09-30 |
2011-07-18 |
Bayer Healthcare Llc |
FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
|
WO2004041302A1
(en)
*
|
2002-11-06 |
2004-05-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
|
ATE431403T1
(de)
|
2003-03-20 |
2009-05-15 |
Bayer Healthcare Llc |
Fvii oder fviia varianten
|
US7897734B2
(en)
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
PL1615945T3
(pl)
|
2003-04-09 |
2012-03-30 |
Ratiopharm Gmbh |
Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
|
DE602004025100D1
(de)
|
2003-05-23 |
2010-03-04 |
Novo Nordisk Healthcare Ag |
Stabilisierung von proteinen in lösung
|
RU2373282C2
(ru)
|
2003-06-19 |
2009-11-20 |
Байер Хелткэр Ллк |
ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
|
ES2382157T3
(es)
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
ES2574581T3
(es)
|
2003-08-14 |
2016-06-20 |
Novo Nordisk Health Care Ag |
Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
|
ES2381110T3
(es)
|
2003-09-09 |
2012-05-23 |
Novo Nordisk Health Care Ag |
Polipéptidos de factor VII de coagulación
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20090043080A1
(en)
*
|
2004-09-29 |
2009-02-12 |
Novo Nordisk Healthcare A/G |
Purification of a Bulk of a Factor VII Polypeptide by Fractionated Elution from an Anion-Exchange Material
|
WO2006050247A2
(en)
|
2004-10-29 |
2006-05-11 |
Neose Technologies, Inc. |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
NZ556436A
(en)
|
2005-01-10 |
2010-11-26 |
Biogenerix Ag |
Glycopegylated granulocyte colony stimulating factor
|
EP2386571B1
(en)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
ES2516694T3
(es)
|
2006-07-21 |
2014-10-31 |
Ratiopharm Gmbh |
Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
BRPI0809670A8
(pt)
|
2007-04-03 |
2018-12-18 |
Biogenerix Ag |
métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
|
CN101778859B
(zh)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
改良的用于生产核苷酸糖的方法
|
CN103497246B
(zh)
|
2008-02-27 |
2016-08-10 |
诺沃—诺迪斯克有限公司 |
缀合的因子viii分子
|
ES2856968T3
(es)
|
2016-01-15 |
2021-09-28 |
Rigshospitalet |
Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
|
MA46864A
(fr)
|
2016-11-17 |
2021-04-28 |
Minerva Imaging Aps |
Facteur vii inhibé par le site actif marqué par 177-lu
|